Information for Vermont Prescribers of Prescription Drugs

LUMRYZ[™] (sodium oxybate) for extended-release oral suspension (CIII)

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.

The prices listed here do not necessarily reflect price per dosage, price per course of treatment, or the cost effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Product Name	Manufacturer	NDC or UPC	AWP
Marketed Product			
LUMRYZ 4.5 g (suspension; oral)	Avadel CNS Pharmaceuticals	13551-001	Non-Pill Product
LUMRYZ 6.0 g (suspension; oral)	Avadel CNS Pharmaceuticals	13551-002	Non-Pill Product
LUMRYZ 7.5 g (suspension; oral)	Avadel CNS Pharmaceuticals	13551-003	Non-Pill Product
LUMRYZ 9.0 g (suspension; oral)	Avadel CNS Pharmaceuticals	13551-004	Non-Pill Product
Other Products			
Sodium Oxybate Oral Solution, CIII 0.5g/mL (solution; oral)	Hikma Pharmaceuticals	0054-9628-57	Non-Pill Product
XYREM [®] 0.5 gm/mL (solution; oral)	Jazz Pharmaceuticals	68727-100-01	Non-Pill Product
XYWAV [®] 0.04 gm/mL; 0.13 gm/mL; 0.096 gm/mL; 0.234 gm/mL (solution; oral)	Jazz Pharmaceuticals	68727-150-01	Non-Pill Product

July 2023

